Colonic Neoplasia

Remotti

Colorectal adenocarcinoma – leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma 57,000.

Colonic Adenocarcinoma (Overview of lecture)


- Precursor lesions (Adenoma- Carcinoma sequence)
- Pathologic staging of colorectal tumors
- Chronic inflammation (IBD, including UC and Crohns)
- Genetics (genetic predisposition)


FAP (germline mutation of APC gene) HNPCC (germline mutation of mismatch repair gene)


- Molecular pathways of colorectal carcinogenesis Suppressor pathway (APC/beta catenin)


Mutator pathway (DNA mismatch repair genes)


Colonic Polyps: Hyperplastic vs. Adenomatous














Colonic Polyps: Hyperplastic vs. Adenomatous MIB-1 (immuno) nuclear staining Adenoma- lacks surface maturation; Hyperplastic Polyp Adenom a

























Polypectomy is only Treatment


IF:

- 1) Stalk margin is negative
- 2) No lymphatic/vascular invasion
- 3) Tumor is <u>not poorly</u> differentiated.


Adenoma – Carcinoma Sequence


Populations that have a high prevalence of adenomas have a high prevalence of colorectal carcinoma.


- •The distribution of adenomas within the colorectum is similar to that of colorectal carcinoma.
- •Peak incidence of adenomas antedates the peak for colorectal carcinoma.
- •Adenomatous epithelium is often co-existent with adenocarcinoma.
- •Screening programs that carefully follow patients for the development of adenomas and remove all that are identified, reduce the incidence of colorectal cancer.














TNM classification of colorectal adenocarcinoma

T-Primary tumor

- Tx Primary tumor cannot be assessed
- TO No evidence of primary tumor
- Tis Carcinoma in situ (intraepithelial or intramucosal invasion of lamina propria)***
- T1 Tumor invades submucosa
- T2 Tumor invades muscularis propria
- T3 Tumor invades through muscularis propria into subserosa or into pericolic/perirectal fat.
- T4 Tumor directly invades other organs or structures and/or perforates visceral peritoneum.
- *** In the colon, unless a tumor invades into the <u>submucosa</u>, it is not considered an invasive adenocarcinoma.

TNM classification of colorectal adenocarcinoma

N-Regional Lymph Nodes

- Nx Regional lymph nodes cannot be assessed
- No No regional lymph node metastasis
- N1 Metastasis in 1 to 3 regional lymph nodes
- N2 Metastasis in 4 or more regional lymph nodes

M- Distant Metastases

- Mx Distant metastasis cannot be assessed
- M0 No distant metastasis
- M1 Distant metastasis

Major classes of proteins encoded by cancer-associated genes: Tumor suppressor genes, DNA repair genes, Protooncogenes, Proteins regulating apoptosis. Growth factor (PDGF, PGF) Growth factor receptor (EGF receptor) (EGF receptor) Cell cycle regulators (cycle inhibitor designal transducer (PAS) Apoptosis inhibitor (Cycle inhibitor pt 6) Apoptosis inhibitor (BCL2) DNA repair (MMSH2) DNA repair (MMSH2) Cell cycle and apoptosis regulators (PRS) (MMSH2)

Familial Adenomatous Polyposis

Familial adenomatous polyposis (FAP)



APC- tumor suppressor gene Germline mutation of APC gene Patients develop thousands of polyps by their 2nd decade. The second APC gene must be lost for adenoma formation.


for adenoma formation.
Virtually 100% risk for developing
Colorectal adenocarcinoma; also
high risk of ampullary carcinoma.



Earliest precursor lesion – "aberrant crypt"



WNT signaling pathway involves APC/beta-catenin and Tcf-4.




In malignant cells with loss of APC, beta catenin degradation is prevented, so WNT signaling response is continually activated.

WNT-soluble factor that induces cellular proliferation by binding to its cytoplasmic receptor Preventing degradation of beta-catenin allowing it to translocate to the nucleus where it acts as a transcriptional activator in conjunction with Tcf-4.

APC protein- antiproliferative effect; integral part of complex that destoys beta-catenin.

HNPCC

Hereditary Non-Polyposis Colon Cancer




HNPCC


Clinical Criteria for HNPCC

Amsterdam criteria: At least 3 relatives with colon cancer and all of the following:

- -One affected person is a first degree relative of the other two affected persons
- -Two successive generations affected.
- -At least one case of colon cancer diagnosed before age 50 y
- -FAP excluded

Modified Amsterdam criteria: same as Amsterdam criteria except cancer can involve (colon, endometrium, small bowel, ureter or renal pelvis) instead of only colon cancer.






Summary of clinical, pathological and genetic features of HNPCC

- Familial clustering of colorectal and/or endometrial cancer
- Excess risk of cancer of the ovary, ureter/renal pelvis, small bowel, stomach, brain, hepatobiliary tract, and skin (sebaceous tumors)
- Development of multiple cancers at an early age
- Features of colorectal adenoma include:
 - i. variable numbers (one to a few)
 - ii. high degree of dysplasia
 - iii. rapid progression from adenoma to carcinoma (additional mutations rapidly accumulate – ACCELERATED TUMORIGENESIS)
 - iv. high frequency of MSI
- Features of colorectal cancer include:
 - i. predilection to proximal colon
 - ii. improved survival
 - iii. multiple colorectal tumors
 - iv. increased proportion of mucinous tumors, poorly differentiated tumors, and tumors with marked host lymphocytic infiltrate at tumor margin.

HNPCC clinical characteristics

HNPCC CLINICAL CHARACTERISTICS		
	HNPCC	Sporadic
Mean age at diagnosis, y	44.6	67
Multiple colon cancers, %	34.5	4 - 11
Synchronous	18.1	3 - 6
Metachronous	24.3	1 - 5
Proximal location, %	72.3	35
Excess malignancies at other sites	Yes	No
Mucinous and poorly differentiated cancers	Common	Infrequent
RER + %	79	17




The progression to solorestal salition is associated with an assumitation of genetic alterations,
including alterations in oncogenes (K-ras), tumor suppressor genes (APC, DCC, p53), and DNA
repair genes (hMSH2, hMLH1). The exact sequence of events is approximate and may vary in
sporadic cancers compared with those arising in hereditary syndromes or inflammatory bowel
disease.


Genes	altoroc	l in col	lon c	ancor

GENES ALTERED IN COLON CANCER				
Gene	Chromosome	Sporadic tumors with alterations, %	Class	Function
K - ras	12	50	Protooncogene	Signal transduction
				?Cell adhesion
APC	5	60	Tumor supressor	
				Anti-proliferative function
DCC	18	70	Tumor supressor	?Cell adhesion
p53	17	75	Tumor supressor	Cell cycle control (G1/S arrest)
hMSH2	2		DNA Mismatch repair	Maintains fidelity of DNA replication
hMLH1	3		DNA Mismatch repair	Maintains fidelity of DNA replication

Dysplasia and Carcinoma in Inflammatory Bowel disease

Dysplasia-associated lesion/mass (DALM) in Ulcerative Colitis






High grade Dysplasia

Risk of dysplasia in UC correlate with EXTENT and DURATION of disease. UC patients with pancolitis are at highest risk. Ulcerative proctitis (disease limited to rectum) -negligible risk.

DALM – (dysplasia associated lesions)

greater than 50% chance of coexistent invasive adenocarcinoma.

Probability of developing colorectal carcinoma in ulcerative colitis




Cumulative risk of developing adenocarcinoma correlates with duration of UC:

5% in 5 years 15% in 25 years 30-50% in 40 years

1% per year cumulative incidence of carcinoma after 10 years duration of disease.

Bresalier RS, Kim YS, In Gastrointestinal Disease: Pathophysiology/Diagnosis/Management, edn 5. Edited by Sleisenger MH, Fordtran JS. Philadelphia: WB Saunders; 1993 1449-1493



Estimates of the predisposing causes of Colorectal Carcinoma

Current screening (average risk)

FOBT	FOBT annual	Positive tests
Flex sig	Flex sig - 5yr	Colonoscopy
Colonoscopy	every 10 yr	
Barium Enema	every 5 yr	

Current screening (increased risk)

1 adenoma <1cm	3-6 yr after initial	Colonoscopy
	polypectomy	
Adenoma>1cm,	3 yrs after	
Multiple adenomas	initial	
	polypectomy	
Curative resection	Within 1 yr	If normal,
of colon cancer		repeat in 3yr.

Current screening (high risk)

FAP (family hx)	puberty	Genetic testing
HNPCC (family hx)	age 21	Genetic testing, 1-2 yr until age 40, then annually
IBD	Risk greater with Pancolitis, >10yr duration	Every 1-2 yr.

Colonic Neoplasia

Colonic Adenocarcinoma (Summary)

- Precursor lesions (Adenoma- Carcinoma sequence)
- Pathologic staging of colorectal tumors
- Chronic inflammation (IBD, including UC and Crohns)
- Genetics (genetic predisposition)

FAP (germline mutation of APC gene) HNPCC (germline mutation of mismatch repair gene)

- Molecular pathways of colorectal carcinogenesis Suppressor pathway (APC/beta catenin) Mutator pathway (DNA mismatch repair genes)